Fulgent reports Q3 total revenue $85M, core revenue up 17% to $66M, GAAP loss $0.44/share

Fulgent Genetics, Inc.

Core revenue (ex-COVID) grew 17% YoY to $66M; total revenue $85M including $19M from COVID reimbursements.
GAAP net loss $13.1M ($0.44 EPS); non-GAAP loss $11.7M ($0.39 EPS) for Q3 2023.
Adjusted EBITDA was $18.1M; cash from operations $10.2M in the quarter.
Cash, cash equivalents, and marketable securities totaled $851M as of Sep 30, 2023.
Fulgent reiterates full-year 2023 core revenue guidance of $260M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Fulgent Genetics, Inc. reported third quarter ended September 30, 2023 results: revenue Total Revenue of $85 million, net income GAAP loss of $13.1 million, or $0.44 per share, EPS GAAP loss of $13.1 million, or $0.44 per share. Guidance reaffirmed.

Period: third quarter ended September 30, 2023
Revenue: Total Revenue of $85 million
Net income: GAAP loss of $13.1 million, or $0.44 per share
EPS: GAAP loss of $13.1 million, or $0.44 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced financial results for its third quarter ended September 30, 2023. Third Quarter 2023 Results: • Total Revenue of $85 million • Core Revenue 1 grew 17% year-over-year to $66 million • GAAP loss of $13.1 million, or $0.44 per share • Non-GAAP loss of $11.7 million, or $0.39 per share • Adjusted EBITDA of $18.1 million • Generated cash flow from operations of $10.2 million • Cash, cash equivalents, and investments in marketable securities of $851 million as of September 30, 2023

View on SEC.gov

Browse all earnings releases →

Fulgent Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-058509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.